Pharmaceuticals

Biosimilar Interleukins Market Growth Projection: Expected to Surpass $41.22 Billion by 2030 at 40.6% CAGR

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the biosimilar interleukins market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Biosimilar Interleukins Market size between 2026 and 2035?

The biosimilar interleukins market has experienced substantial expansion in recent years. This market is anticipated to surge from $7.52 billion in 2025 to $10.54 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 40.2%. The historical development in this sector can be ascribed to several factors, including the elevated cost of originator interleukin biologics, the increasing incidence of autoimmune and inflammatory diseases, the rising burden of rheumatoid arthritis and psoriasis, limited patient accessibility to biologic therapies, and an increasing understanding of biologics in immune modulation.

The biosimilar interleukins market is set to experience considerable growth in the upcoming years, with projections indicating it will reach $41.22 billion by 2030, advancing at a compound annual growth rate (CAGR) of 40.6%. This expansion during the forecast period is attributed to the expiration of patents for branded interleukins, the broadening of biosimilar clinical pipelines, increasing acceptance of biosimilars by physicians, supportive government policies promoting biosimilar usage, and a rising need for affordable biologic cancer and immunology treatments. Prominent trends expected in this period include the increased adoption of biosimilar interleukins in treating autoimmune diseases, a growing demand for economical alternatives to originator biologics, the expansion of biosimilar approvals for various indications, the greater utilization of interleukins in chronic inflammatory disorders, and the strengthening of regulatory frameworks that facilitate biosimilar adoption.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp

Which Drivers Are Impacting Market Performance In The Biosimilar Interleukins Market?

The rising occurrence of autoimmune conditions such as psoriasis and rheumatoid arthritis is projected to fuel expansion in the interleukin biosimilars market during the forecast period. These disorders involve immune cells failing to differentiate between healthy cells and potentially harmful antibodies. Biologic treatments, specifically anti-interleukin antibodies, have demonstrated substantial clinical advantages in managing cell regulation, as well as directing their proliferation, activation, and migration. For example, reports from February 2024 by the National Institutes of Health (NIH), a US-based biomedical research agency, indicate that the global annual increases in the incidence and prevalence of autoimmune diseases are estimated at 19.1% and 12.5%, respectively. Consequently, the growing prevalence of autoimmune diseases is boosting demand for the biosimilar interleukins market and is anticipated to propel market growth.

Which Segments Are Contributing To The Growth Of The Biosimilar Interleukins Market?

The biosimilar interleukins market covered in this report is segmented –

1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6

2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Subsegments:

1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management

2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment

3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders

4) By IL-5: Asthma Treatment, Eosinophilic Disorders

5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment

What Trends Are Expected To Impact The Competitive Landscape Of The Biosimilar Interleukins Market?

Companies operating in the biosimilar interleukins market are introducing new products like Tofidence (tocilizumab-bavi) to enhance their profitability. Tofidence is a monoclonal antibody designed to target and bind to interleukin-6 receptors, used in treating various inflammatory autoimmune disorders. For example, in September 2023, Biogen Inc., a US-based biotechnology company, obtained FDA approval for Tofidence (tocilizumab-bavi), marking it as the first biosimilar referencing Genentech’s Actemra (tocilizumab). Tofidence is given via intravenous infusion and has been approved for treating severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Who Are The Major Companies Operating In The Biosimilar Interleukins Market?

Major companies operating in the biosimilar interleukins market are Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Biosimilar Interleukins Market?

North America was the largest region in the biosimilar interleukins market in 2025. The regions covered in the biosimilar interleukins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biosimilar Interleukins Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3433&type=smp

Browse Through More Reports Similar to the Global Biosimilar Interleukins Market 2026, By The Business Research Company

Generic Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795